George Canellos Carmela Pepe John Goldman Roy Herbst Sandra Horning George Canellos, from the Dana-Farber Cancer Institute in Boston, joins Derek Thorne to talk about the first day’s news at the
George Canellos
Carmela Pepe
John Goldman
Roy Herbst
Sandra Horning
George Canellos, from the Dana-Farber Cancer Institute in Boston, joins Derek Thorne to talk about the first day’s news at the ASCO annual meeting in Atlanta.
– Elderly patients with non-small cell lung cancer can benefit from chemotherapy after surgery, and do not experience increased toxicity when compared to younger patients – that’s according to Carmela Pepe of the Princess Margaret Hospital in Toronto (abstract 7009)
– the Oncology Drugs Advisory Committee has concluded that the drug dasatinib should be recommended for the treatment of chronic myeloid leukaemia. Breaking the news at the Atlanta meeting was John Goldman of Imperial College London, and the National Heart Lung and Blood Institute, NIH, Bethesda
– Roy Herbst from the MD Anderson Cancer Center in Houston tells the Audio Journal about some of the most exciting announcements to be made at the 2006 ASCO conference, including progress in multiple myeloma and targeted therapy in renal cancer
– the outgoing president of ASCO, Sandra Horning, of Stanford University, explains how ASCO has focussed on cancer survivorship over the last year – and how cancer survivors can expect to receive more support in the future.
[audio:https://www.audiomedica.com/podcasting/asco/06.06.03_ASCO_podcast.mp3]
Related Episodes
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon